Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration

NCT00304954 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

13

Enrollment

NIH

Sponsor class

Conditions

Age-Related Macular Degeneration
Choroidal Neovascularization

Interventions

DRUG: Intravenous Daclizumab
DRUG: Intravenous Infliximab
OTHER: Observation
DRUG: Oral Rapamycin

Sponsor

National Eye Institute (NEI)